Anti-complement factor C1q Fab fragments and uses thereof
AssigneeAnnexon, Inc.
InventorsTed Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
Claims19
A method of inhibiting synapse loss comprising administering to a patient suffering from adverse synapse loss an antibody Fab fragment that binds to C1q, wherein the antibody Fab fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises SEQ ID NO:1 and the light chain comprises SEQ ID NO:2.
A method of treating a disease associated with C1q mediated activation of the classical complement pathway in an individual in need of such treatment, the method comprising administering an antibody Fab fragment that binds to C1q, wherein the antibody Fab fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises SEQ ID NO:1 and the light chain comprises SEQ ID NO:2.
Dependencies are inferred from the claim text.